Epitopea is a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies for hard-to-treat solid tumors.
Epitopea’s pipeline is built on Cryptigen™ TSAs, a new class of tumor-specific antigens identified by CryptoMap™, the company’s proprietary immunopeptidomics and genomics platform that uncovers aberrantly expressed antigens arising from previously uncharacterised regions of the genome.
The company’s lead candidate, CryptiVax™-1001, is an off-the-shelf mRNA therapeutic vaccine in development for high-grade serous ovarian cancer. It is designed to drive targeted immune responses using a set of tumor-specific antigens chosen for broad patient coverage. Many patients with advanced cancers, including high-grade serous ovarian cancer, have limited durable treatment options and few effective therapies beyond biomarker-selected populations. Epitopea aims to address this unmet need with broadly applicable, tumor-selective immunotherapies.
Backed by leading life-science investors, Epitopea operates from Cambridge, UK, and Montreal, Canada. For more information, visit
www.epitopea.com and follow the company on
LinkedIn.
